Abstract
Lymphomas represent a very heterogeneous group of hematological malignancies and, despite successful therapies, they are a major challenge in clinical practice. Lymphomas often develop resistance to treatment with standard of care drugs (SoC) and have a high relapse rate. Therefore, new therapies are needed to improve long-term remission and patient survival. Recent advances in high-throughput molecular profiling have helped to identify genetic factors and genetic subtypes of diffuse large B-cell lymphoma (DLBCL).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
